Glenmark Pharmaceuticals Ltd revenue from operations jumped 35.1% year-on-year to ₹3,387.6 crore, vs ₹2,506.7 crore during Q3 ...

For the quarter ended December 31, 2024, the company recorded revenue from operations of ₹431 crore, up 29.5% YoY.

GNPA spiked to 6.17%, compared with 3.88% in the previous quarter, while Net NPA up 2.5% from 0.89%, signalling asset quality ...

Between February 10-14, 2025, the US FDA conducted an inspection to ensure compliance with US pharmaceutical manufacturing ...

Aditya Birla Fashion revenue from operations increased by 3.3% YoY to ₹4,304.7 crore as compared with ₹4,166.7 crore ...

EBITDA fell 21.8% YoY to ₹47.7 crore, against ₹61 crore in the previous year, with EBITDA margin declining to 31.7% from 37.9 ...

Alembic Pharmaceuticals net profit dropped 23% YoY to ₹138.4 crore in Q3 FY25 from ₹180.4 crore in the same quarter of last ...

On the sell side, the fund cut positions in Infosys and Sun Pharma. The fund’s top 5 stock picks for January 2025 based on ...

However, the company stated that its revenue from operations registered a growth of 66.90% to ₹534.70 Crore in Q3FY25.

After the core inflation fell to 3.58% in December 2024, it has bounced back to 3.70% in January 2025. This is due to the ...

The deal is aimed at improving operational efficiency, expanding capabilities, and fuel innovation in the maritime sector.

Reliance Industries Q2 profit reported a net profit rose 7% to ₹18,540 crore in Q3 FY25 from ₹17,265 crore in Q3 FY24.